The online version of this article (https://doi.org/10.1007/s10549-019-05149-4) contains supplementary material, which is available to authorized users.
Preliminary data were presented at the Breast Cancer Meeting (Bossche Mammadagen) 2018 in The Netherlands.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
To evaluate the impact of chemotherapy on subjective cognitive functioning according to age in a large cohort of breast cancer patients.
Within the UMBRELLA cohort, 715 patients with early-stage primary invasive breast cancer (T1-3N0-1M0) were selected. Subjective cognitive function was assessed by means of the EORTC QLQ-C30 up to 24 months and compared between patients treated with and without chemotherapy, for three different age strata (355 patients < 55 years, 240 patients aged 55–65 years, and 120 patients > 65 years). Differences between chemotherapy and non-chemotherapy patients by age at different time points were assessed by linear mixed-effect models correcting for age, tumor stage, educational level, endocrine therapy, anxiety, and depression.
In total, 979 patients from the UMBRELLA cohort were included, of which 715 (73%) responded to baseline and at least one follow-up questionnaire. Questionnaire response rates ranged between 92 and 70%. The proportion of patients treated with chemotherapy decreased with age: 64% (n = 277) in patients < 55 years, 45% (n = 107) in patients 55–65 years, and 23% (n = 27) in patients > 65 years. Chemotherapy was associated with reduced subjective cognitive functioning. The impact of chemotherapy on subjective cognitive function was most pronounced in patients < 55 years, followed by those between 55 and 65 years. In the youngest age groups, patients treated with chemotherapy had significantly lower cognitive functioning up to 24 months. In women over 65 years, subjective cognitive functioning was comparable between patients treated with and without chemotherapy.
This study confirms that chemotherapy is associated with impaired subjective self-reported cognitive functioning in breast cancer patients, and the effect persists at least up to 2 years after diagnosis. The impact of chemotherapy on self-reported cognitive functioning in the first 24 months is most pronounced in younger patients, especially those under 55 years of age.
Holzel D, Eckel R, Bauerfeind I, Baier B, Beck T, Braun M et al (2017) Improved systemic treatment for early breast cancer improves cure rates, modifies metastatic pattern and shortens post-metastatic survival: 35-year results from the Munich Cancer Registry. J Cancer Res Clin Oncol 143(9):1701–1712 CrossRefPubMed
Early Breast Cancer Trialists’ Collaborative Group (EBCTCG), Peto R, Davies C, Godwin J, Gray R, Pan HC et al (2012) Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials. Lancet 379(9814):432–444 CrossRef
Wefel JS, Saleeba AK, Buzdar AU, Meyers CA (2010) Acute and late onset cognitive dysfunction associated with chemotherapy in women with breast cancer. Cancer 116(14):3348–3356 CrossRef
Schagen SB, Muller MJ, Boogerd W, Rosenbrand RM, van Rhijn D, Rodenhuis S et al (2002) Late effects of adjuvant chemotherapy on cognitive function: a follow-up study in breast cancer patients. Ann Oncol 13(9):1387–1397 CrossRef
Young-Afat DA, van Gils CH, van den Bongard HJGD, Verkooijen HM, UMBRELLA Study Group (2017) The Utrecht cohort for Multiple BREast cancer intervention studies and Long-term evaLuAtion (UMBRELLA): objectives, design, and baseline results. Breast Cancer Res Treat 164(2):445–450 CrossRefPubMedPubMedCentral
Risicoprofilering Richtlijn Mammacarcinoom (2012) Kwaliteitsinstituut voor de gezondheidszorg CBO VvIK, pp 81–83
Netherlands Cancer Registry (2018) http://www.cijfersoverkanker.nl. Accessed May 2018
van de Poll-Franse LV, Horevoorts N, van Eenbergen M, Denollet J, Roukema JA, Aaronson NK et al (2011) The Patient Reported Outcomes Following Initial treatment and Long term Evaluation of Survivorship registry: scope, rationale and design of an infrastructure for the study of physical and psychosocial outcomes in cancer survivorship cohorts. Eur J Cancer 47(14):2188–2194 CrossRefPubMed
Fayers PM, Aaronson NK (2001) The EORTC QLQ-C30 scoring manual, 3rd edn. European Organisation for Research and Treatment of Cancer, Brussels
’Cohen J (1988) Statistical power analysis for the behavioral sciences, 2nd edn. Lawrence Erlbaum, Hillsdale
Quesnel C, Savard J, Ivers H (2009) Cognitive impairments associated with breast cancer treatments: results from a longitudinal study. Breast Cancer Res Treat 116(1):113–123 CrossRef
Janelsins MC, Heckler CE, Peppone LJ, Kamen C, Mustian KM, Mohile SG et al (2017) Cognitive complaints in survivors of breast cancer after chemotherapy compared with age-matched controls: an analysis from a nationwide, multicenter, prospective longitudinal study. J Clin Oncol 35(5):506–514 CrossRefPubMed
Mandelblatt JS, Clapp JD, Luta G, Faul LA, Tallarico MD, McClendon TD et al (2016) Long-term trajectories of self-reported cognitive function in a cohort of older survivors of breast cancer: CALGB 369901 (Alliance). Cancer 2016 122(22):3555–3563
Schilder CM, Eggens PC, Seynaeve C, Linn SC, Boogerd W, Gundy CM et al (2009) Neuropsychological functioning in postmenopausal breast cancer patients treated with tamoxifen or exemestane after AC-chemotherapy: cross-sectional findings from the neuropsychological TEAM-side study. Acta Oncol 48(1):76–85 CrossRef
Cardoso F, van’t Veer LJ, Bogaerts J, Slaets L, Viale G, Delaloge S et al (2016) 70-Gene signature as an aid to treatment decisions in early-stage breast cancer. N Engl J Med 375(8):717–729 CrossRef
- The effect of chemotherapy on subjective cognitive function in younger early-stage breast cancer survivors treated with chemotherapy compared to older patients
M. L. Gregorowitsch
D. A. Young-Afat
I. O. Baas
C. van Schaik-van de Mheen
M. J. Agterof
D. ten Bokkel Huinink
H. J. G. D. van den Bongard
H. M. Verkooijen
UMBRELLA study group
- Springer US
Neu im Fachgebiet Onkologie
Mail Icon II